Related Experiment Video
Updated: May 13, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Supra-physiological efficacy at GPCRs: superstition or super agonists?
Christopher J Langmead1, Arthur Christopoulos
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
British Journal of Pharmacology
|February 28, 2013
Summary
Super agonists, peptide hormone analogues, may elicit stronger responses than natural agonists. Recent data combining pharmacology, GPCR structures, and advanced analytical methods suggest these compounds are a real phenomenon, not just superstition.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- The concept of 'super agonism' emerged in the early 1980s with peptide hormone analogues.
- Debate has persisted regarding whether these analogues truly exhibit greater efficacy than endogenous agonists.
- Defining and verifying super agonism has been challenging due to limitations in analytical methods and understanding of receptor dynamics.
Purpose of the Study:
- To re-evaluate the phenomenon of super agonism in light of recent scientific advancements.
- To provide pharmacological and structural evidence supporting the existence of super agonists.
- To clarify the mechanisms underlying super agonism and its implications in drug action.
Main Methods:
- Utilized advanced pharmacological assays to quantify drug-receptor interactions and functional responses.
- Incorporated crystal structures of G protein-coupled receptors (GPCRs) in various conformations.
- Employed cutting-edge analytical techniques for precise measurement of drug action and efficacy.
Main Results:
- Recent pharmacological data provide strong evidence for the existence of super agonists.
- Crystal structures reveal distinct GPCR conformations that can be stabilized by super agonists.
- Improved analytical methods allow for accurate quantification of responses exceeding those of endogenous agonists.
Conclusions:
- Super agonists are a pharmacologically validated phenomenon, not merely a theoretical concept.
- The ability of certain analogues to elicit greater functional responses than endogenous agonists is supported by new evidence.
- Further research into super agonists could unlock novel therapeutic strategies targeting GPCRs.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:30Spare Receptors
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...